Medulloblastoma (MB) is the most common malignant pediatric brain tumor. Dysregulation of WNT signaling occurs in up to 20% of cases. Using a genome-wide approach, we identified the secreted frizzled-related protein 1, 2 and 3 (SFRP1, SFRP2 and SFRP3) family of WNT inhibitors as putative tumor suppressor genes silenced by promoter region methylation in MB. SFRP1, SFRP2 and SFRP3 expression increased after 5-aza-2 0 -deoxycytidine treatment. SFRP1, SFRP2 and SFRP3 methylation was identified in 23.5, 3.9 and 15.7% of primary MB specimens, respectively, by methylationspecific PCR. Stable SFRP1, SFRP2 and SFRP3 expression reduced phospho-DVL2 levels and hindered MB cell proliferation and colony formation in soft agar in vitro. In 60% of primary tumors, SFRP1 was expressed at levels twofold lower than that in normal cerebellum. SFRP1 expression impaired tumor formation in vivo in flank and orthotopic intracerebellar xenograft models and conferred a significant survival advantage (Po0.0001). We identify for the first time tumor suppressor gene function of SFRP genes in MB, and suggest that loss of WNT pathway inhibition due to SFRP gene silencing is an additional mechanism that may contribute to excessive WNT signaling in this disease.
Introduction
Medulloblastoma (MB) is the most common malignant posterior fossa tumor. Dysregulation of developmental signaling pathways, including WNT signaling, is known to have a major role in MB pathogenesis. WNT signaling is crucial for normal cerebellar development, as transgenic mice with reduced WNT signaling exhibit cerebellar aplasia (McMahon and Bradley, 1990) . Turcot syndrome patients with germline adenomatous polyposis coli (APC) gene mutation and resultant increased WNT signaling have an increased risk of MB (Hamilton et al., 1995) . Furthermore, mutations affecting WNT signaling members (APC, CTNNB1, AXIN1 and AXIN2) are seen in 15-20% of sporadic MB cases (Eberhart et al., 2000; Baeza et al., 2003; Thompson et al., 2006; Koch et al., 2007) .
Recent gene expression profiling studies show that human MBs may be divided into distinct molecular subgroups including one characterized by expression of markers of canonical WNT signaling such as WIF1, DKK2, LEF1, KREMEN1 and AXIN2 (Thompson et al., 2006; Kool et al., 2008; Northcott et al., 2009a) . Most tumors in the WNT subgroup have monosomy 6, activating CTNNB1 mutations, and carry a more favorable prognosis compared with other MB subgroups (Eberhart et al., 2000; Ellison et al., 2005; Kool et al., 2008; Northcott et al., 2009a) .
Recently, we used a microarray-based genome-wide epigenetic approach to identify novel tumor suppressor genes silenced by promoter methylation in MB (Kongkham et al., 2008) . Among candidates identified were members of the secreted frizzled-related protein (SFRP) family of WNT inhibitors, including SFRP1, SFRP2 and SFRP3. Functionally, SFRP genes can limit canonical and noncanonical WNT signaling, binding WNT ligand and sequestering it away from Fz receptors (Bovolenta et al., 2008) . SFRPs have been identified as tumor suppressor genes whose expression is reduced in a variety of malignancies (Dahl et al., 2007) . Only SFRP1 has been examined in the context of MB previously. SFRP1 expression has been shown to increase after treatment of the D283 cell line with the histone deacetylase inhibitor, trichostatin, but the functional significance of this was not examined (Vibhakar et al., 2007) . A second study looking at SFRP1 in MB failed to identify promoter methylation, which may have been in part due to the limited number of tumors examined (Chang et al., 2005) .
Here, we show for the first time that SFRP1, SFRP2 and SFRP3 promoter region methylation is associated with gene silencing in MB cell lines and primary tumors.
Expression of SFRP1, SFRP2 or SFRP3 in MB cells reduces their proliferative capacity and anchorageindependent growth in vitro. SFRP1, SFRP2 or SFRP3 expression limits WNT signaling, as evidenced by reduced levels of phospho-DVL2. SFRP1 expression also limits tumor burden and prolongs overall survival in vivo in an intracranial xenograft model of MB.
Results and discussion
SFRP1, SFRP2 and SFRP3 silencing is associated with promoter region methylation Increased expression of SFRP1, SFRP2 and SFRP3 after 5-aza-2 0 -deoxycytidine (5-aza-dC) treatment in MB cell lines was validated using quantitative real-time PCR. SFRP1 expression increased in the ONS76, UW228, UW426, D425, D458 and MED8A cell lines after treatment (Figure 1a ). SFRP2 expression increased in the UW228 cell line, and SFRP3 in the DAOY, D283 and MED8A cell lines (Supplementary Figure 1) . Bisulfite sequencing confirmed promoter region methylation for SFRP1, SFRP2 and SFRP3 in MB cell lines compared with normal fetal and adult cerebellum ( Figure 1b and Supplementary Figures 2 and 3) . Methylation-specific PCR identified methylation of the SFRP1, SFRP2 and SFRP3 promoter regions in 12/51 (23.5%), 2/ 51 (3.9%) and 8/51 (15.7%) primary MB specimens, respectively ( Figure 1c and Supplementary Figure 4) . Where sufficient mRNA was available, SFRP1 expression was correlated with SFRP1 promoter methylation status by quantitative real-time PCR. Samples identified as having aberrant promoter region methylation by methylationspecific PCR showed low levels of SFRP1 gene expression compared with normal cerebellum (Figure 1d ). SFRP1, SFRP2 and SFRP3 re-expression reduces WNT signaling, cell proliferation and anchorage-independent growth To determine the functional significance of SFRP1, SFRP2 and SFRP3 silencing in MB, we stably expressed each gene individually in the D283 and ONS76 MB cell lines and assessed the effect on WNT signaling, cell proliferation and colony formation in soft agar compared with both empty vector and an EGFP-expressing control stable cell lines (Figure 2 and Supplementary  Figures 5-8) .
SFRPs exert their effect upstream at the level of the WNT ligand-Fz receptor interaction, and may therefore influence both canonical and/or noncanonical WNT signaling downstream. In addition, MB cell lines (including D283 and ONS76) do not possess a canonical WNT signaling expression profile or cytogenetic abberations such as monosomy 6, characteristics typical of WNT subgroup MBs (Northcott et al., 2009a, b) . Therefore, to determine the effect of SFRP expression on WNT signaling, we examined levels of phospho-DVL2, upstream of the point of divergence into the canonical and noncanonical pathways (Habas and Dawid, 2005) . SFRP1, SFRP2 and SFRP3 expression MB subgroup-specific expression of SFRP1 Using Affymetrix Genechip Human Exon Arrays (Affymetrix, Santa Clara, CA, USA) to assess gene expression in a large cohort of 103 primary MBs, 7 MB cell lines, 9 fetal and 5 adult cerebellar samples, we observed SFRP1 expression levels to be more than twofold lower in 60% (62/103) of primary MBs compared with normal cerebellum. Unsupervised hierarchical clustering based on 1450 differentially expressed genes divided primary tumors into four molecular subgroups (WNT, Sonic hedgehog (SHH) homolog, Group C and Group D) as described by our group and others (Thompson et al., 2006; Kool et al., 2008; Northcott et al., 2009a) . Interestingly, SFRP1 expression was reduced in WNT, Group C and Group D MB subgroups in comparison with the SHH group of tumors (Figure 3a) .
A common feature of WNT subgroup tumors is the presence of downstream activating CTNNB1 mutations. One might question the functional significance of reduced SFRP1 expression in the context of downstream activating mutations. However, it has been shown in the context of colorectal cancer that loss of SFRP gene expression in the presence of downstream mutations of APC or activating CTNNB1 mutations function in a synergistic fashion, and that expression of SFRPs can reduce WNT signaling even in the presence of downstream activating mutations (Suzuki et al., 2004) .
Interestingly, SFRP1 expression was also reduced in Group C and Group D tumors that do not possess canonical WNT gene expression signatures (Figure 3a) . This suggests the possibility that lack of SFRP1 expression in these tumors may influence MB pathogenesis through dysregulation of noncanonical WNT signaling pathways. As mentioned, MB cell lines, including D283 and ONS76, cluster separately from the canonical WNT MB subgroup based on Exon Array gene expression data (Northcott et al., 2009a) . In addition, they lack the cytogenetic marker of monosomy 6 associated with canonical WNT tumors, but rather possess an isochromosome 17q and either gain or amplification of MYC-markers associated with Group C and Group D tumors (Northcott et al., 2009b) .
In contrast, the SHH MB subgroup continues to express SFRP1 (Figure 3a) . Maintained SFRP1 expression in the SHH subgroup may be owing to the fact that SFRP1 is a known SHH signaling target (Katoh and Representative SFRP1 expression by an unmethylated MB specimen is included for comparison. Katoh, 2006) . SFRP1 expression is seen in both human MB and murine models of MB in which SHH signaling is upregulated (Lee et al., 2003; Thompson et al., 2006; Kool et al., 2008) . An important question is whether or not SFRP1 exerts a tumor suppressor gene effect on SHHdriven tumors. It is possible that SHH-driven tumors tolerate high levels of SFRP1 expression without suffering deleterious effects from reduced WNT signaling activity.
The SHH MB subgroup is believed to originate from cerebellar granule neuron precursor cells (Fan and Eberhart, 2008; Gilbertson and Ellison, 2008) . WNT signaling has not been shown to influence the proliferative capacity or hedgehog responsiveness of this population of precursor cells (Gilbertson and Ellison, 2008) . In contrast, tumors of the WNT, Group C and Group D subtypes may arise from distinct precursor cells residing in the cerebellar subventricular zone or white matter, and thus may represent cell populations susceptible to alterations in WNT signaling activity (Fan and Eberhart, 2008; Gilbertson and Ellison, 2008) .
Another possibility is that SHH subgroup tumors remain susceptible to the tumor suppressor effects of SFRP1, and are kept in check by its expression. As existing MB cell lines do not faithfully represent this MB subgroup, determining the functional significance of SFRP1 expression in SHH-driven tumors may require further study using hedgehog-driven murine models of MB or granule neuron precursor cells derived from such models.
Mechanisms contributing to low-level SFRP1 expression
As SFRP1 expression was twofold lower in 60% (62/103) of primary MBs compared with normal cerebellum, whereas SFRP1 promoter region methylation was identified in only 23.5%, we sought to determine whether additional mechanisms may target SFRP1 for silencing. The SFRP1 gene locus on chromosome 8p is a frequent target for loss of heterozygosity in a variety of malignancies including MB (Northcott et al., 2009b) . We previously reported results from a high-resolution single-nucleotide polymorphism array study looking at 201 primary human MBs, in which losses targeting chromosome 8, including the SFRP1 locus, were observed in 31/201 (15%) tumors (Figure 3b ) (Northcott et al., 2009b) . Chromosome 8p loss occurred with increased frequency in Group C and Group D tumors, and was associated with a trend toward reduced SFRP1 expression (Figure 3c ). SFRP1 may also be influenced by transcription factor-mediated repression. The MYC transcription factor is known to bind to the SFRP1 promoter region, strongly repressing SFRP1 transcription (Cowling et al., 2007) . On the basis of Exon Array data, the top quartile of MYC expressors ('high MYC group') showed reduced SFRP1 expression compared with the bottom quartile of MYC expressors ('low MYC group') ( Figure 3d ). Although not examined specifically here, modifications to the histone code may also contribute to SFRP1 gene silencing in the absence of promoter region methylation.
SFRP1 expression impairs MB tumor formation in vivo
To examine the effect of SFRP1 expression on MB growth in vivo, we employed both flank and orthotopic intracerebellar xenograft models (Figure 4 ). ONS76 cells stably transfected with empty vector or pcDNA3.1-SFRP1-FLAG were injected into the left and right hind flanks of immunodeficient mice, respectively. As seen in Figure 4a , 5/5 tumors formed in the left flank when injected with empty vector-transfected cells. In comparison, SFRP1 re-expressing cells formed tumors in only 1/5 mice. Mice engrafted intracranially with empty vector-transfected D283 MB cells quickly succumbed to symptoms related to tumor progression, with a mean overall survival of 27.6 ± 1.3 days. SFRP1 expression in D283 cells conferred a significant survival advantage in this orthotopic xenograft model (Po0.0001) (Figure 4b ). All mice engrafted with SFRP1-expressing D283 cells remained alive and asymptomatic for 60 days, at which time the data were censored and specimens collected for further characterization. All mice engrafted with empty vector-transfected cells developed large cerebellar lesions (Figure 4c ). In contrast, tumors from SFRP1-transfected cells were considerably smaller and in some cases not grossly visible on hematoxylin and eosin staining (Figure 4c ).
Conclusions
In summary, using a genome-wide epigenetic strategy, we identified SFRP1, SFRP2 and SFRP3 as candidate tumor suppressor genes in MB and verified their methylation in MB cell lines and primary tumors. Functionally, SFRP1, SFRP2 and SFRP3 expression limited WNT signaling, reduced MB cell proliferation and anchorage-independent growth in vitro. SFRP1 expression reduced tumor burden leading to increased overall survival in vivo. We observed low-level expression of SFRP1 in 60% of primary human MB samples in comparison with normal cerebellum. Reduced SFRP1 expression was observed in the WNT, Group C and Group D MB molecular subgroups in comparison with SHH-driven tumors. We acknowledge the limitations of using nonmatched human fetal and adult whole cerebellar tissue samples for normal controls as one area of weakness in this and other studies in this field. Given the difficulties in obtaining normal cerebellar tissue samples as well as an incomplete understanding regarding the cell of origin for various MB subtypes, these samples represent one of the best normal human tissue controls currently available.
In addition to epigenetic mechanisms including promoter region methylation, SFRP1 expression may be influenced by gene deletion events or transcription factor-mediated silencing. Aberrant canonical WNT signaling has been firmly implicated in MB pathogenesis. Our study is the first to identify loss of pathway inhibition due to SFRP gene silencing as an additional mechanism contributing to dysregulation of WNT signaling in MB. 6 ONS76 cells stably transfected with empty vector or pcDNA3.1-SFRP1-FLAG were injected into the flank of nude mice and followed up for 10 weeks. (b) Kaplan-Meier survival curve for intracerebellar xenografts using stably transfected D283-empty vector cells (EV) or D283-SFRP1 cells (SFRP1). A significant survival advantage was conferred by SFRP1 expression, with all SFRP1 mice remaining asymptomatic at 60 days (Po0.0001). 1 Â 10 5 D283 cells stably transfected with empty vector or pcDNA3.1-SFRP1-FLAG were stereotactically injected orthotopically into the midline cerebella of 10 nude mice per group. Mice were killed when displaying evidence of significant intracranial mass effect or a loss of 20% body weight was observed. The experiment was censored at 2 months, when remaining mice were killed and examined by hematoxylin and eosin staining and immunostaining for SFRP1 (R&D Systems, Minneapolis, MN, USA). (c) Hematoxylin and eosin staining and immunohistochemistry for SFRP1 in representative intracerebellar xenograft specimens. Empty vector controls produced large tumors (arrow) with leptomeningeal spread (arrowhead). SFRP1 expression significantly reduced tumor burden (arrow).
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